Mallinckrodt PLC CEO Confronts Short Seller Andrew Left But Doesn't Appear to Answer His QuestionsMark Melin
Troubled health care roll-up artist Valeant is like a bunch of “choir boys” when compared pharmaceutical concern Mallinckrodt, short seller Andrew Left of Citron Research said on CNBC Wednesday after the close, where he was confronted by the firm's CEO.
Left was short and vocal regarding Valeant, says its the tip of . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email email@example.com and we will get back to you as quick as humanly possible